CINXE.COM
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
<!DOCTYPE html> <html lang="en"> <head id="Head1"><meta charset="utf-8" /><title> Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements </title><link href="../../../../Content/Site.css" rel="stylesheet" /><link href="../../../../Content/bootstrap-3.3.2-dist/css/bootstrap.min.css" rel="stylesheet" /><link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet" /><link href="../../../../Content/Custom.css" rel="stylesheet" /><link href="../../../../Content/CustomSubPage.css" rel="stylesheet" /><link href="../../../favicon.ico" rel="shortcut icon" type="image/x-icon" /> <script src="/Scripts/modernizr-2.5.3.js"></script> <meta name="viewport" content="width=device-width" /> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery-latest.min.js"> </script> <script type="text/javascript" src="https://www.jcnnewswire.com/jquery/jquery.fancybox.pack.js?v=2.1.5"></script> <link rel="stylesheet" type="text/css" href="https://www.jcnnewswire.com/jquery/jquery.fancybox.css?v=2.1.5" media="screen"> <style> .lang li { display:inline; } .lang a { color:#fff; } </style> </head> <body> <form method="post" action="./Anticancer-Agent-TASFYGO-Tablets-35mg-(Tasurgratinib-Succinate)-Launches-in-Japan-for-Biliary-Tract-" onsubmit="javascript:return WebForm_OnSubmit();" id="Form1"> <div class="aspNetHidden"> <input type="hidden" name="__EVENTTARGET" id="__EVENTTARGET" value="" /> <input type="hidden" name="__EVENTARGUMENT" id="__EVENTARGUMENT" value="" /> <input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="/wEPDwUJMjIwMDIyMjcyZGS0ekUELnr7FYRFBayAUtI+MBQgRY3lLoCt+eATxa6w8Q==" /> </div> <script type="text/javascript"> //<![CDATA[ var theForm = document.forms['Form1']; if (!theForm) { theForm = document.Form1; } function __doPostBack(eventTarget, eventArgument) { if (!theForm.onsubmit || (theForm.onsubmit() != false)) { theForm.__EVENTTARGET.value = eventTarget; theForm.__EVENTARGUMENT.value = eventArgument; theForm.submit(); } } //]]> </script> <script src="/WebResource.axd?d=YcG_1mlPARhRW7O4sA9bWHA-qI2d_t_BO06OeFBhoaiREhheyXs3-1psdTUSDOHCoQeBPKlq2r8vu_cSQNfig-Is-AxTXJhRKwfH8V2oM9c1&t=638628512640000000" type="text/javascript"></script> <script src="/WebResource.axd?d=bIpPyEdzAMer_bwfyhWa6rFaO8WGfxnN2PvV0BTsVTDvSo40Rw6pGSZlPV1TZTu152c0lKoeiKGVeRIzWI8ylmApYjdRpTU999mo98-2hDs1&t=638628512640000000" type="text/javascript"></script> <script type="text/javascript"> //<![CDATA[ function WebForm_OnSubmit() { if (typeof(ValidatorOnSubmit) == "function" && ValidatorOnSubmit() == false) return false; return true; } //]]> </script> <div class="aspNetHidden"> <input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="864D2D71" /> <input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="/wEdAAO8tONZ7TayD33kmU+szqoisK8Qcg6x7YEKBpnNUn26Cy8zACrOsmKsedR3ZCAsXqM/dy/xKCWXHGLwmCk3EueWC1wJCXuvUmCTQwrK8AlK4w==" /> </div> <header> <div style="background-color:#000;"> <div class="content-wrapper"> <div style="color:#fff;padding-bottom:22px;"> <span style="float:right;"> <ul class="lang"> <li style="font-size:12px;color:#ABA9A9;"> <a href="/"> TOP PAGE</a> </li> <li style="font-size:12px;color:#ABA9A9;"> </li> <li style="font-size:12px;color:#ABA9A9;background-color: #E55657; padding-top: 8px; padding-bottom: 4px; padding-left: 3px;"> <a href="/english/"> ENGLISH</a> </li> <li style="font-size:12px;color:#ABA9A9;"> </li> <li style="font-size:12px;color:#ABA9A9;"><a href="/japanese/"> JAPANESE</a></li> <li style="font-size:12px;color:#ABA9A9;"> | </li> <li style="font-size:12px;color:#fff;"> CONNECT WITH US:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </span> </div> </div> </div> <br /> <div class="content-wrapper"> <div class="feature-float-left"> <p class="site-title"><a href="../../../" id="A1"> <img src="/Images/JCN-Newswire.jpg" width="300px"/></a></p> </div> <div class="float-right"> <section id="login"> <ul> </ul> <ul class="the-icons"> </ul> </section> </div> <div class="row"> <div class="col-md-12 col-md-12-nav"> <nav class="topnav"> <ul class="nav nav-tabs"> <li role="presentation"><a href="../../../" id="A3">Home</a></li> <li role="presentation"><a href="../../../About/" id="A4">About</a></li> <li role="presentation"><a href="../../../services/" id="A13">Services</a></li> <li role="presentation"><a href="../../../Contact/" id="A5">Contact</a></li> <li role="presentation"><a href="http://client.japancorp.net" id="A6">Log in</a></li> <li style="padding-top:5px;"> <span id="RequiredFieldSearch" style="color:White;visibility:hidden;">*</span> <input name="ctl00$searchstring" type="text" id="searchstring" placeholder="Search for..." style="width:150px;height:30px;font-size:14px;" /><input type="submit" name="ctl00$SearchButton" value="Go!" onclick="javascript:WebForm_DoPostBackWithOptions(new WebForm_PostBackOptions("ctl00$SearchButton", "", true, "", "", false, false))" id="SearchButton" class="btn btn-default" type="submit" style="height:30px;font-size: 13px;margin-left:2px;background-color:#f2f2f2;border-color:#ccc;" /> </li> </ul> </nav> </div> </div> </div> </header> <div id="body"> <section class="content-wrapper main-content clear-fix"> <!-- Go to www.addthis.com/dashboard to customize your tools --> <script type="text/javascript" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=ra-54f7fe387839d451" async="async"></script> <ol class="breadcrumb"> <li><a href="/english/">Home</a></li> <li class="active">Press release</li> </ol> <table> <!-- Body --> <tr valign="top"><td> <div class="col-lg-12 clearfix"> <table width="100%"> <tr> <td> <div id="MainContent_CompanyInfo"> <span id="MainContent_releaseDate" class="small">Nov 20, 2024 10:24 JST</span><br /> <span id="MainContent_companyLogo"><img src="http://www.jcnnewswire.com/image/company/eisai.240.jpg" class="companyLogo"></span><br /> <span id="MainContent_companySource" class="small">Source: <a href="http://www.eisai.com" target="_blank">Eisai</a></span> </div> </td> <td class="float-right"> <div class="addthis_sharing_toolbox"></div> </td> </tr> </table> </div> <p style="padding-bottom:100px;"></p> <div class="col-lg-9"> <table> <tr><td> <div align="justify" class="title"><span id="MainContent_HeadLine" class="header">Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements</span></div> <div align="justify"><strong></strong></div> <div align="justify"><span id="MainContent_Body" class="bodytext"><p><strong>TOKYO, Nov 20, 2024 - (JCN Newswire) - </strong>Eisai Co., Ltd. announced today that it has launched fibroblast growth factor receptor (FGFR) selective tyrosine kinase inhibitor “TASFYGO® Tablets 35mg” (generic name: tasurgratinib succinate) in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. The product received manufacturing and marketing approval in Japan on September 24, 2024, and was published in Japan’s National Health Insurance Drug Price List today.<br><br><img style="display: block; margin-left: auto; margin-right: auto;" src="https://photos.acnnewswire.com/TASFYGO.jpg" alt="" width="380" height="214"></p> <p>Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against FGFR1, FGFR2 and FGFR3.</p> <p>The approval of TASFYGO in Japan is based on data such as the results of a multicenter, open-label, single- arm clinical phase II trial (Study 201) conducted by Eisai in Japan and China.1 A companion diagnostic test to detect FGFR2 gene fusions or rearrangements for the use of TASFYGO in biliary tract cancer, “AmoyDx® FGFR2 Break-apart FISH Probe Kit” by Nihon Stery, Inc. (Headquarters: Tokyo) was approved in August 2024.(2)</p> <p>The estimated number of patients in Japan with biliary tract cancer is approximately 22,000,(3),(4) with approximately 25% of the five-year relative survival rate,(3) making it an intractable cancer with the second worst prognosis following pancreatic cancer. Since drug therapy options are limited in comparison with other cancers, it is a disease with significant unmet medical needs. FGFR2 gene fusions or rearrangements are observed in approximately 5-14% of intrahepatic cholangiocarcinoma, which accounts for 15-30% of biliary tract cancers.(5),(6),(7) FGFR genetic aberrations such as the gene fusions are known to be deeply involved in the proliferation, survival and migration of cancer cells as well as tumor angiogenesis and drug resistance. As these genetic aberrations in FGFRs have been observed in various other types of cancers as well as biliary tract cancer, there is growing interest in FGFRs as a promising target for cancer therapy.</p> <p>TASFYGO is produced at the Kawashima Industrial Park (Gifu Prefecture), using innovative Continuous Manufacturing and Real Time Release Testing, a manufacturing technology that ensures product quality within production processes. Continuous Manufacturing is a production method in which processing is carried out continuously from raw material input to formulation. By incorporating real-time quality monitoring technology, multiple manufacturing processes are integrated, enabling automatic production. This method allows for higher quality control compared to conventional processes that focus on product release testing, by utilizing data within the manufacturing process and reducing human-error through automation.</p> <p>Eisai aims to make continuous efforts to meet the diversified needs of and increase the benefits provided to patients with cancer, their families, and healthcare professionals, by delivering TASFYGO as a new treatment option for biliary tract cancer with FGFR2 gene fusions or rearrangements.</p> <p><strong>Product Information</strong></p> <p>Brand name: TASFYGO® Tablets 35mg Generic name: Tasurgratinib succinate</p> <p>Indications: Unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy</p> <p>Dosage and Administration: The usual adult dose of tasurgratinib is 140mg orally once daily under fasting conditions. The dose may be reduced appropriately according to the condition of the patient.</p> <p>National Health Insurance (NHI) Drug Price: TASFYGO Tablets 35 mg: ¥ 15,378.70 (per 1 tablet) Packaging: TASFYGO Tablets 35 mg: 56 tablets (14 tablet PTP sheet X 4)</p> <p><strong>About “TASFYGO® Tablets 35mg” (tasurgratinib succinate, Development Code: E7090)</strong></p> <p>Discovered in-house by Eisai’s Tsukuba Research Laboratories, TASFYGO is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3. Distinct from prior known FGFR inhibitors, TASFYGO has a basic structure which lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that TASFYGO demonstrates antitumor activities due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR.(8),(9)</p> <p>In non-clinical studies for biliary tract cancer, NIH/3T3 cells expressing FGFR2-AHCYL1, FGFR2-KCTD1, FGFR2-BICC1 or FGFR2-TXLNA as FGFR2-fusion genes, provided by the National Cancer Center Japan, were used. The antitumor activity of TASFYGO against FGFR2 gene fusion-positive cancers was confirmed in these models by evaluating its effect on anchorage-independent growth and subcutaneously transplanted tumor growth in mice.(9)</p> <p>A Phase I clinical trial is underway in Japan in patients with estrogen receptor-positive and HER2-negative breast cancer.</p> <p><strong>About Real Time Release Testing</strong></p> <p>Real Time Release Testing is a quality control approach that ensures the quality of final products based on data from within the manufacturing process. Applying Real Time Release Testing requires a quality design approach based on Quality by Design (QbD), an advanced development method for manufacturing processes. QbD is a development method that emphasizes process control based on profound understanding of manufacturing processes, rather than conventional quality assurance methods which mainly focus on product release testing.</p> <p>Eisai integrates Process Analytical Technology (PAT) into QbD to achieve a higher level of quality control by managing critical attributes of pharmaceuticals within the production process.</p> <p>(1) Furuse J. et al. Pivotal single-arm, phase 2 trial of tasurgratinib for patients with fibroblast growth factor receptor (FGFR)-2 gene fusion-positive cholangiocarcinoma (CCA). 2024 ASCO Gastrointestinal Cancers Symposium; Abstract No. 471. <a href="https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.3_suppl.471">https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.3_suppl.471</a><br>(2) AmoyDx® FGFR2 Break-apart FISH Probe Kit Approved as Companion Diagnostic for Eisai’s Tasurgratinib in Japan. Available at: https://www.amoydiagnostics.com/about/press-releases/245 Last accessed: September 2024.<br>(3) Latest statistics, Cancer Information Service, National Cancer Center, Japan. (Japanese only)<br>(4) The 23rd Follow-up Survey Reports for Primary Liver Cancer Cases in Japan (2014-2015), 2023. (Japanese only)<br>(5) Arai Y. et al., Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma, Hepatology, 2014, 59, 1427-1434.<br>(6) Maruki Y. et al., Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study), J Gastroenterol. 2021; 56(3), 250-260.<br>(7) Tsujie M. et al., Fibroblast growth factor receptor 2 (FGFR2) fusions in Japanese patients with intrahepatic cholangiocarcinoma, Jpn J Clin Oncol. 2021; 51(6): 911-917.<br>(8) Miyano SW. et al., E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models, Molecular Cancer Therapeutics, 2016, 15, 2630-2639.<br>(9) Kawano S. et al., Antitumor Activity of Tasurgratinib as an Orally Available FGFR1-3 Inhibitor in Cholangiocarcinoma Models With FGFR2-fusion, Anticancer Research, 2024, 44, 2393-2406.</p> <p>Media Inquiries:<br>Public Relations Department, Eisai Co., Ltd.<br>+81-(0)3-3817-5120</p></span></div> <div align="justify"><span id="MainContent_CompanyName" class="bodytext"></span></div> <div align="justify"><span id="MainContent_CompanyBoiler" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Contact" class="bodytext"></span></div> <div align="justify"><span id="MainContent_Source" class="note">Source: Eisai<BR />Sectors: Healthcare & Pharm <BR /><BR /></span></div> <div align="justify"><span id="MainContent_Copyright" class="bodytext"><p>Copyright 漏2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.<p></span></div> </td></tr> </table> </div> <div class="col-lg-3"> <span id="MainContent_RelatedNews_RelatedNews"><div><h4>Related Press Release</h4><hr /><table width="100%" cellpadding=0 cellspacing=0><tr><td><a href="/english/pressrelease/96056/3/Development-of-Prediction-Model-for-Brain-Amyloid-Beta-Accumulation-for-Early-Screening-of-Alzheimer">Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease</a></td></tr><tr><td class="note">February 14 2025 11:09 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95722/3/Eisai-to-Provide-Guidance-on-Reducing-the-Risk-of-Cognitive-Decline-and-Nutrition,-and-Development-G">Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies</a></td></tr><tr><td class="note">February 03 2025 16:23 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95573/3/FDA-Approves-LEQEMBI-(lecanemab-irmb)-IV-Maintenance-Dosing-for-the-Treatment-of-Early-Alzheimer&apo">FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a></td></tr><tr><td class="note">January 28 2025 08:46 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95425/3/Eisai-Listed-as-a-Global-100-Most-Sustainable-Corporation-for-The-Ninth-Time-Highest-Ranked-Global-P">Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company</a></td></tr><tr><td class="note">January 22 2025 16:18 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95256/3/FDA-Accepts-LEQEMBI-(lecanemab-irmb)-Biologics-License-Application-for-Subcutaneous-Maintenance-Dosi">FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease</a></td></tr><tr><td class="note">January 15 2025 09:03 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/95040/3/Elucidation-of-part-of-the-Mechanism-by-which-Lecanemab-Slows-the-Progression-of-Alzheimer&aposs-Dis">Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease</a></td></tr><tr><td class="note">January 07 2025 08:14 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94804/3/Fujirebio-and-Eisai-Enter-into-Memorandum-of-Understanding-for-Joint-Research-and-Social-Implementat">Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases</a></td></tr><tr><td class="note">December 23 2024 16:22 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94481/3/Eisai&aposs-"URECE(R)"-(Dotinurad)-Approved-in-China-for-Gout-Patients-with-Hyperuricemia">Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia</a></td></tr><tr><td class="note">December 11 2024 13:45 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94344/3/"LEQEMBI"-(Lecanemab)-Approved-for-the-Treatment-of-Early-Alzheimer&aposs-Disease-in-Mexico">"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico</a></td></tr><tr><td class="note">December 05 2024 10:22 JST</td></tr><tr><td> </td></tr><tr><td><a href="/english/pressrelease/94158/3/LEQEMBI-(Lecanemab)-for-the-Treatment-of-Alzheimer&aposs-Disease-Launched-in-South-Korea">LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea</a></td></tr><tr><td class="note">November 28 2024 15:26 JST</td></tr><tr><td> </td></tr><tr><td align="center"><a href="/english/CompanyNews/93990/3">More Press release >></a></td></tr></table></dl></div></span> <br /> <h4><span id="MainContent_Label1">Latest Press Release</span></h4> <hr /> <span id="MainContent_LatestRelease_LatestPressRelease"><table width="100%" cellpadding=0 cellspacing=0><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/english/pressrelease/96133/3/TOYOTA-GAZOO-Racing-starts-WEC-season-with-Qatar-challenge" class="newslink">TOYOTA GAZOO Racing starts WEC season with Qatar challenge</a><br /><span class="note"> Feb 17, 2025 18:45 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/english/pressrelease/96131/3/FLAT-OUT-IN-TOKYO-Red-Bull-Showrun-x-Powered-by-Honda-April-2-(Wed)" class="newslink">FLAT OUT IN TOKYO "Red Bull Showrun x Powered by Honda" April 2 (Wed)</a><br /><span class="note"> Feb 17, 2025 16:21 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/english/pressrelease/96129/3/Thrilling-TOYOTA-GAZOO-Racing-one-two-on-Swedish-snow" class="newslink">Thrilling TOYOTA GAZOO Racing one-two on Swedish snow</a><br /><span class="note"> Feb 17, 2025 14:23 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Corporation" src="http://www.jcnnewswire.com/image/toppage/MC.68.jpg"><br /><a href="/english/pressrelease/96127/3/Launch-of-Joint-Demonstration-Experiment-of-Remote-Provision-of-GPU-Computing-Power" class="newslink">Launch of Joint Demonstration Experiment of Remote Provision of GPU Computing Power</a><br /><span class="note"> Feb 17, 2025 14:10 JST</span><br /></td></tr><tr><td class="articleDate"><img title="mazda" src="http://www.jcnnewswire.com/image/toppage/MazdaLogo.48.jpg"><br /><a href="/english/pressrelease/96066/3/Mazda-to-Strengthen-Production-and-Sales-Systems-in-Thailand" class="newslink">Mazda to Strengthen Production and Sales Systems in Thailand</a><br /><span class="note"> Feb 14, 2025 17:04 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Toyota Motor Corporation" src="http://www.jcnnewswire.com/image/toppage/ToyotaBb.68.jpg"><br /><a href="/english/pressrelease/96060/3/Toyota-Develops-New-Fuel-Cell-System" class="newslink">Toyota Develops New Fuel Cell System</a><br /><span class="note"> Feb 14, 2025 15:27 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Eisai" src="http://www.jcnnewswire.com/image/toppage/eisai45.jpg"><br /><a href="/english/pressrelease/96056/3/Development-of-Prediction-Model-for-Brain-Amyloid-Beta-Accumulation-for-Early-Screening-of-Alzheimer" class="newslink">Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease</a><br /><span class="note"> Feb 14, 2025 12:09 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Motors" src="http://www.jcnnewswire.com/image/toppage/MMT1902.jpg"><br /><a href="/english/pressrelease/96017/3/Nissan,-Honda-and-Mitsubishi-Motors-terminate-MOU-regarding-consideration-of-tripartite-collaboratio" class="newslink">Nissan, Honda and Mitsubishi Motors terminate MOU regarding consideration of tripartite collaboration</a><br /><span class="note"> Feb 13, 2025 16:20 JST</span><br /></td></tr><tr><td class="articleDate"><img title="ANA InterContinental Tokyo" src="http://www.jcnnewswire.com/image/toppage/ANA_InterContinental_S.jpg"><br /><a href="/english/pressrelease/95903/3/ANA-InterContinental-Tokyo-unveils-Icon-Reborn-transformation" class="newslink">ANA InterContinental Tokyo unveils Icon Reborn transformation</a><br /><span class="note"> Feb 13, 2025 15:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/english/pressrelease/96010/3/MHI-Thermal-Systems-Receives-Top-Honors-on-Australias-Foremost-Consumer-Review-Platform-for-Two-Seri" class="newslink">MHI Thermal Systems Receives Top Honors on Australia's Foremost Consumer Review Platform for Two Series of Split System Air-Conditioners</a><br /><span class="note"> Feb 13, 2025 12:47 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Honda Motor Co, Ltd" src="http://www.jcnnewswire.com/image/toppage/honda.gif"><br /><a href="/english/pressrelease/96008/3/Honda-Presents-World-Premiere-of-Seven-Refreshed-Large-size-Outboard-Motors-at-the-Miami-Internation" class="newslink">Honda Presents World Premiere of Seven Refreshed Large-size Outboard Motors at the Miami International Boat Show 2025</a><br /><span class="note"> Feb 13, 2025 10:50 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/english/pressrelease/96007/3/Fujitsu-to-offer-Fujitsu-Cloud-Service-Generative-AI-Platform-for-secure-and-flexible-enterprise-dat" class="newslink">Fujitsu to offer Fujitsu Cloud Service Generative AI Platform for secure and flexible enterprise data management</a><br /><span class="note"> Feb 13, 2025 10:01 JST</span><br /></td></tr><tr><td class="articleDate"><img title="ULVAC, Inc." src="http://www.jcnnewswire.com/image/toppage/Ulvac.64.jpg"><br /><a href="/english/pressrelease/95891/3/ULVAC-Develops-Roll-to-Roll-Lithium-Deposition-System,-Unveiling-at-Battery-Japan" class="newslink">ULVAC Develops Roll-to-Roll Lithium Deposition System, Unveiling at Battery Japan</a><br /><span class="note"> Feb 13, 2025 08:30 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Power" src="http://www.jcnnewswire.com/image/toppage/mitsubishipower.68.jpg"><br /><a href="/english/pressrelease/95973/3/Mitsubishi-Power-Secures-Major-Gas-Turbine-and-Services-Order-for-Al-Wahda-Open-Cycle-Gas-Turbine-Po" class="newslink">Mitsubishi Power Secures Major Gas Turbine and Services Order for Al Wahda Open Cycle Gas Turbine Power Plant in Morocco</a><br /><span class="note"> Feb 12, 2025 16:21 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Mitsubishi Heavy Industries, Ltd." src="http://www.jcnnewswire.com/image/toppage/MHI_newT.jpg"><br /><a href="/english/pressrelease/95964/3/MHI-Delivers-Final-7000-Series-AGT-Trainset-for-the-Astram-Line" class="newslink">MHI Delivers Final 7000-Series AGT Trainset for the Astram Line</a><br /><span class="note"> Feb 12, 2025 12:24 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Fujitsu Ltd" src="http://www.jcnnewswire.com/image/toppage/Fujitsu.Logo.68.jpg"><br /><a href="/english/pressrelease/95960/3/Fujitsu-and-Yokohama-National-University-achieve-worlds-first-real-time-prediction-of-tornadoes-asso" class="newslink">Fujitsu and Yokohama National University achieve world's first real-time prediction of tornadoes associated with typhoons using supercomputer Fugaku</a><br /><span class="note"> Feb 12, 2025 11:37 JST</span><br /></td></tr><tr><td class="articleDate"><img title="NEC Corporation" src="http://www.jcnnewswire.com/image/toppage/NEC.62.jpg"><br /><a href="/english/pressrelease/95896/3/NEC-Solution-Modernizes-Network-Infrastructure-Construction-Work" class="newslink">NEC Solution Modernizes Network Infrastructure Construction Work</a><br /><span class="note"> Feb 10, 2025 15:05 JST</span><br /></td></tr><tr><td class="articleDate"><img title="Olympus" src="http://www.jcnnewswire.com/image/toppage/Olympus65.jpg"><br /><a href="/english/pressrelease/95890/3/Olympus-Recognized-on-CDPs-A-List,-the-Highest-Rating-in-the-Field-of-Climate-Change" class="newslink">Olympus Recognized on CDP's "A List", the Highest Rating in the Field of Climate Change</a><br /><span class="note"> Feb 10, 2025 11:00 JST</span><br /></td></tr><tr><td class="articleDate"><img title="uSMART" src="http://www.jcnnewswire.com/image/toppage/uSMART68.jpg"><br /><a href="/english/pressrelease/95851/3/uSMART-Capital,-LLC-officially-approved-for-US-FINRA-license" class="newslink">uSMART Capital, LLC officially approved for U.S. FINRA license</a><br /><span class="note"> Feb 07, 2025 17:40 JST</span><br /></td></tr><tr><td class="articleDate"><img title="TANAKA PRECIOUS METAL GROUP Co., Ltd." src="http://www.jcnnewswire.com/image/toppage/Tanaka_New_Logo_s1.jpg"><br /><a href="/english/pressrelease/95788/3/TANAKA-to-Provide-Medals-for-the-Tokyo-Marathon-2025-That-Represent-All-the-Participants-in-the-Even" class="newslink">TANAKA to Provide Medals for the Tokyo Marathon 2025 That Represent All the Participants in the Event with Woven Lines</a><br /><span class="note"> Feb 07, 2025 04:00 JST</span><br /></td></tr></table></span> <a id="MainContent_LatestRelease_MoreRelease" href="/english/MoreNews/3/">More Latest Release >></a> </div> </td></tr> </table> <script type="text/javascript"> $(document).ready(function () { $("#single_1").fancybox({ helpers: { title: { type: 'float' } } }); }); </script> </section> </div> <footer> <div class="content-wrapper"> <div align="center"> Copyright © 2025 - JCN Newswire <div class="botton-nav"> <ul> <li><a href="../../../../" id="A7">Home</a></li> <li><a href="../../../about/" id="A8">About</a></li> <li><a href="../../../contact/" id="A9">Contact</a></li> <li><a href="../../../../rssfeed/" id="A10">RSS</a></li> <li><a href="../../../Cookies/">Cookies Policy</a></li> <li><a href="../../../Disclaimer/">Disclaimer</a></li> <li><a href="../../../Privacy/">Privacy Policy</a></li> <li><a href="../../../Terms/">Terms of Use</a></li> <li> - </li> <li> Connect with us:</li> <li class="nolink"> <a href="https://www.facebook.com/jcnnewswire" target="_blank" class="social"> <i class="fa fa-facebook-square"></i></a> </li> <li class="nolink"> <a href="https://twitter.com/JCNNewswire" target="_blank" class="social"><i class="fa fa-twitter-square"></i></a> </li> <li class="nolink"> <a href="/rssfeed/" class="social"><i class="fa fa-rss-square"></i></a> </li> </ul> </div> </div> </div> </footer> <script type="text/javascript"> //<![CDATA[ var Page_Validators = new Array(document.getElementById("RequiredFieldSearch")); //]]> </script> <script type="text/javascript"> //<![CDATA[ var RequiredFieldSearch = document.all ? document.all["RequiredFieldSearch"] : document.getElementById("RequiredFieldSearch"); RequiredFieldSearch.controltovalidate = "searchstring"; RequiredFieldSearch.errormessage = "*"; RequiredFieldSearch.evaluationfunction = "RequiredFieldValidatorEvaluateIsValid"; RequiredFieldSearch.initialvalue = ""; //]]> </script> <script type="text/javascript"> //<![CDATA[ var Page_ValidationActive = false; if (typeof(ValidatorOnLoad) == "function") { ValidatorOnLoad(); } function ValidatorOnSubmit() { if (Page_ValidationActive) { return ValidatorCommonOnSubmit(); } else { return true; } } //]]> </script> </form> <script> (function (i, s, o, g, r, a, m) i['GoogleAnalyticsObject'] = r; i[r] = i[r] || function () (i[r].q = i[r].q || []).push(arguments) }, i[r].l = 1 * new Date(); a = s.createElement(o), m = s.getElementsByTagName(o)[0]; a.async = 1; a.src = g; m.parentNode.insertBefore(a, m) })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga'); ga('create', 'UA-61831624-1', 'auto'); ga('send', 'pageview'); </script> </body> </html>